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Alemtuzumab is approved for the treatment of relapsing-remitting MS and is used off-label for
patients with chronic lymphocytic leukemia and as induction and antirejection therapy in
kidney transplant recipients.1 Guillain-Barre´ syndrome (GBS) or chronic inflammatory de-
myelinating polyradiculoneuropathy (CIDP) complicating alemtuzumab treatment was
reported in 9 patients with hematologic malignancy or MS.1–3 The risk of GBS or CIDP in solid
organ transplant recipients treated with alemtuzumab is unknown.
Rabbit antithymocyte globulin (rATG) is another T cell–depleting drug used to treat acute kidney
allograft rejection. Only 1 patient was reported who developed GBS after rATG treatment for
aplastic anemia.4 We found no reports of GBS or CIDP complicating rATG treatment in kidney
transplant recipients. Here, we investigated the frequency, type, and outcome of GBS and CIDP in
a single-center cohort of kidney transplant recipients treated with either alemtuzumab or rATG.
Methods
Study design
A retrospective analysis was performed of a cohort of kidney transplant recipients who received
either alemtuzumab (Campath, Sanofi-Genzyme, Cambridge, MA) or rATG (Thymoglobulin,
Sanofi-Genzyme) between 2002 and 2018 in the Erasmus MC, Rotterdam. Alemtuzumab was
administered as a single dose of 30mg subcutaneously and rATG in a dose of 4mg/kg and nog g/kg.
Statistical methods
Continuous variables are presented as median and interquartile ranges (IQRs). The 95% CIs
were calculated with the modifiedWald method. For statistical analysis, SPSS version 21 (SPSS
Inc., Chicago, IL) was used.
Standard protocol approvals, registrations, and patient consents
The study was approved by the Erasmus MCMedical Ethical Review Board (number 2018-1430).
Results
Between 2002 and 2018, 2,788 patients received a kidney transplant at our center. Alemtu-
zumab was administered to 143 (5.1%) patients and rATG to 108 (3.9%) patients. The total
follow-up period of patients treated with alemtuzumab was 3.0 years (IQR 1.7–4.1 years) for
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Table Clinical characteristics, diagnosis, and outcome of patients with GBS and CIDP after alemtuzumab
Case 1 (GBS) 2 (GBS) 3 (CIDP)
Sex Male Female Male
Age at onset symptoms (y) 54 57 63
Primary kidney disease Polycystic kidney disease Reflux nephropathy Polycystic kidney disease
CMV status at transplantation Seropositive Seronegative Seropositive
Induction therapy Alemtuzumab (30mg, 30 days before transplantation, IVIg 0.4 g/kg on the day of
transplantation), immunoabsorption
Basiliximab Basiliximab
Antirejection therapy None Alemtuzumab (30 mg) Alemtuzumab (30 mg)
Immunosuppressive treatment at onset
symptoms
Tacrolimus/MMF/prednisolone 5 mg/d Tacrolimus/MMF/prednisolone 2.5 mg/d Tacrolimus/MMF/prednisolone 5 mg/d
Diagnosis GBS, level 2 of Brighton classification (no electrophysiologic studies available) GBS (AIDP), level 1 of Brighton
classification
CIDP (fulfillment of clinical criteria and
definite electrophysiologic criteria EFNS/PNS
2010)
Interval between alemtuzumab
treatment and symptoms (mo)
4 8 42
Onset to maximum severity (d) 21 10 90
Maximum mRS score (range 0–6) 4 5 4
Maximum GBS disability score (range 0–6) 4 5 —
EGOS (range 0–7) 3.5 6.5 —
Treatment IVIg (0.4 g/kg) for 5 days IVIg (0.4 g/kg) for 5 days 2× IVIg (0.4 g/kg) for 5 days, 4 sessions of
plasma exchange, methylprednisolone (3×
1000 mg), prednisone 5 mg daily
(maintenance)
mRS score after treatment 1 6 1
GBS disability score after treatment of GBS 1 6 —
Neurologic outcome at the last follow-up Partial recovery (follow-up 1 year) Death (6 months later, due to
malignancy)
Full recovery (follow-up 3 years)
Abbreviations: AIDP = acute inflammatory demyelinating polyradiculoneuropathy; CIDP = chronic inflammatory demyelinating polyradiculoneuropathy; EGOS = Erasmus GBS Outcome Score; GBS = Guillain-Barre´ syndrome;
IVIg = IV immunoglobulin; MMF = mycophenolate mofetil; mRS = modified Rankin Scale.
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a total of 444.3 person-years. A tacrolimus-based immuno-
suppressive regimen was given to 92% of patients. Three
patients (2.1%, 95% CI 0.4%–6.3%) developed GBS or CIDP
after alemtuzumab. Two patients fulfilled the diagnostic cri-
teria for GBS, and 1 fulfilled the diagnostic criteria for CIDP.
The clinical presentation and diagnostic findings of these
patients are presented in the table. Laboratory tests, including
clinical chemistry, serology, and virology, demonstrated no
alternative diagnoses, and there was no recent Campylobacter
jejuni or cytomegalovirus infection (PCR negative for cyto-
megalovirus). The total follow-up period for rATG-treated
patients was 8.2 (IQR 6.3–11) years for a total of 829.4
person-years. Seventy-eight percent of patients received
a tacrolimus-based immunosuppressive regimen. None of the
patients treated with rATG (0%, 97.5% CI 0–4.1%) de-
veloped GBS or CIDP.
Discussion
This study shows that 2.1% of patients treated with alemtu-
zumab developed GBS or CIDP. This is higher than the in-
cidence rate of these neuropathies in the general population
and of kidney transplant recipients not treated with
alemtuzumab.5–7 Secondary autoimmunity after alemtuzumab
appears to be mainly B cell driven. A mismatched re-
constitution of T and B cells after alemtuzumab can lead to an
expansion of B cells in the absence of appropriate T-cell reg-
ulation. This may enable the escape of autoreactive B cells and
production of pathogenic autoantibodies to self-antigens,
which can lead to secondary autoimmunity, such as thyroid-
itis, idiopathic thrombocytopenic purpura, GBS, or CIDP.1
None of the patients treated with rATG developed GBS or
CIDP. A possible explanation for the difference in the risk of
developing these neuropathies with alemtuzumab is that the
depletion of immune cells lasts longer after alemtuzumab.1
Alternatively, rATG may protect from GBS and CIDP.
Limitations of the current study are that we were unable to
define the frequency of GBS and CIDP in kidney transplant
recipients not treated with T cell–depleting therapy. Second,
no causality between alemtuzumab and the risk of GBS or
CIDP was demonstrated, and our findings may therefore relate
to chance. Third, cytomegalovirus could have played a role in
the development of GBS or CIDP because patients 1 and 3
were seropositive for cytomegalovirus at the time of trans-
plantation. However, no signs of a reactivation were observed
at the time the patients were diagnosed with GBS and CIDP.
Fourth, we cannot exclude that the increased incidence of GBS
and CIDP among alemtuzumab-treated patients may relate to
the fact that in this group, more patients used tacrolimus as
maintenance immunosuppression compared with the rATG
cohort. Fifth, this observation is based on kidney transplant
recipients who have several reasons to have an underlying
neuropathy (i.e., renal insufficiency and diabetes mellitus), and
it is uncertain whether it is also applicable to patients with MS.
In conclusion, alemtuzumab therapy in kidney transplant
recipients may be associated with the development of GBS
and CIDP. Clinicians should be alert for these neurologic
complications in kidney transplant recipients treated with
alemtuzumab.
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In the Clinical/Scientific Note, “Guillain-Barre´ syndrome and chronic inflammatory de-
myelinating polyradiculoneuropathy after alemtuzumab therapy in kidney transplant recipi-
ents,” byM. van der Zwan et al.,1 the final sentence under the “Study Design” subheading of the
Methods section should read “Alemtuzumab was administered as a single dose of 30 mg
subcutaneously and rATG in a dose of 4 mg/kg.” The publisher and authors regret the error.
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